Medpace Holdings: Downgrade To 'Buy' As Revenue Growth Remains, But With Caution Ahead
Barclays Maintains Equal-Weight on Medpace Holdings, Lowers Price Target to $450
BMO Capital Maintains Market Perform on Medpace Holdings, Lowers Price Target to $400
RBC Capital Maintains Outperform on Medpace Holdings, Lowers Price Target to $484
Loading...